Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able ...

Natural supplements have “very mild effects” on weight loss based on what Dr. Ali has seen. There is some data to suggest ...

This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on ...

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

A large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple ...

Karla Robinson, MD and Medical Editor at GoodRx discusses how GLP-1 receptor agonists work and their benefits.

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery ...

While drugmakers Novo Nordisk and Eli Lilly assert that shortages of popular weight loss and diabetes medications Wegovy, Ozempic, Mounjaro and Zepbound are easing, many patients continue to face ...

Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x ...